Key result
Rotigaptide at 50 nmol/L markedly decreased atrial fibrillation duration in a canine model of chronic mitral regurgitation (96% reduction, P<0.001), but did not affect AF vulnerability in the HF model.
Why the study?
Does rotigaptide improve atrial conduction and reduce AF vulnerability in canine models of chronic mitral regurgitation and heart failure?
Does rotigaptide improve atrial conduction and reduce AF vulnerability in canine models of chronic mitral regurgitation and heart failure?
p-value: p=<0.001
Gap junction modulation with rotigaptide reduces AF vulnerability in a canine model of chronic mitral regurgitation but not in a heart failure model.
No takes yet. Share an insight, caveat, or question.
Rotigaptide effects in MR models warrant clinical exploration; leaves open translation to HF and patients.
Palmero et al. (2006) studied Atrial fibrillation vulnerability in chronic mitral regurgitation and heart failure (n=21). Rotigaptide (ZP123) vs. Baseline / Control animals was evaluated on Conduction velocity and atrial fibrillation duration (p=<0.001). Rotigaptide at 50 nmol/L markedly decreased atrial fibrillation duration in a canine model of chronic mitral regurgitation (96% reduction, P<0.001), but did not affect AF vulnerability in the HF model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: